Lantern Pharma (LTRN) Share-based Compensation (2021 - 2026)
Lantern Pharma's (LTRN) quarterly Share-based Compensation came in at $262915.0 in Q1 2026, up 77.95% YoY from $147750.0 in Q1 2025, and up 170.35% on a QoQ basis from -$373710.0 in Q4 2025.
Lantern Pharma (LTRN) Share-based Compensation (2021 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 6 years of Share-based Compensation data on file, last reported at $262915.0 in Q1 2026.
- Quarterly Share-based Compensation rose 77.95% year-over-year to $262915.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $193516.0 (down 74.08% YoY) and the FY2025 annual result came in at $78351.0, down 89.31% from the prior year.
- Share-based Compensation advanced to $262915.0 in Q1 2026, from -$373710.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $392390.0 in Q2 2023 to a low of -$373710.0 in Q4 2025.
- A 5-year average of $192876.7 and a median of $190755.0 in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation surged 184.57% — and 2025, when it tumbled 230.9%.
- Tracing LTRN's Share-based Compensation over 5 years: stood at $330095.0 in 2022, then plunged by 69.61% to $100325.0 in 2023, then surged by 184.57% to $285499.0 in 2024, then plunged by 230.9% to -$373710.0 in 2025, then surged by 170.35% to $262915.0 in 2026.
- The last three Share-based Compensation figures came in at $262915.0 (Q1 2026), -$373710.0 (Q4 2025), and $143685.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lantern Pharma | 26.05 Mn | 26.05 Mn | - | 262,915.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 262,915.00 |
| Mar 31, 2026 | 262,915.00 |
| Dec 31, 2025 | -373,710.00 |
| Dec 31, 2025 | -373,710.00 |
| Sep 30, 2025 | 143,685.00 |
| Sep 30, 2025 | 143,685.00 |
| Jun 30, 2025 | 160,626.00 |
| Jun 30, 2025 | 160,626.00 |
| Mar 31, 2025 | 147,750.00 |
| Mar 31, 2025 | 147,750.00 |
| Dec 31, 2024 | 285,499.00 |
| Dec 31, 2024 | 285,499.00 |
| Sep 30, 2024 | 179,166.00 |
| Sep 30, 2024 | 179,166.00 |
| Jun 30, 2024 | 134,171.00 |
| Jun 30, 2024 | 134,171.00 |
| Mar 31, 2024 | 134,057.00 |
| Mar 31, 2024 | 134,057.00 |
| Dec 31, 2023 | 100,325.00 |
| Dec 31, 2023 | 100,325.00 |